WASHINGTON (AP) — A panel of federal health experts has ruled that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked in long-term studies.
The Food and Drug Administration's panel of diabetes experts voted 10-5 in favor of J&J's canagliflozin to treat type 2 diabetes. The drug is part of a new class of medications that work by increasing the levels of blood sugar excreted via urine.
Panelists said the drug could be useful in combination with existing diabetes medications. However, they raised concerns about low levels of heart attack, stroke and urinary tract infections seen in the first year of testing. Almost all panelists recommended that the company track those problems over time to tell whether they get worse.
Legal Community Mourns Passing Of Justice Scalia, ‘One Of The Greatest Justices Our Country Has Known’ | Matt Vespa
New Jersey Man Slays Child | Human Events
Media Matters offended by #GOPdebate moderator's 'slur against undocumented immigrants'
- Former Fed Chairman Alan Greenspan Makes Startling Admission
The Craziest GOP Debate of The Cycle: Trump Defends Planned Parenthood, Cruz and Rubio Spar, Audience Boos
MAGNETIC BUCKSHOT- Unexpected Results! - [VIDEO]
The dominant player at the GOP debate was… the audience
Trump Was the Biggest Loser during the South Carolina Debate | RedState